m+Medelevator.RU
← Поиск публикаций
Maturitas · 2026

Considerations in Breast cancer screening, density and supplemental imaging in average-risk women.

СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Harper Laura, Sparling Kennedy, Anderson Sarah, Simmons Curtis L, Fraker Jessica, Patel Bhavika K, Sanders Jeremiah, Leming Macy, Zhu Alan, Sharpe Richard

Аннотация

Breast cancer remains a prevalent health concern, affecting approximately one in eight women during their lifetime. While screening mammography has significantly reduced mortality through early detection, its sensitivity is compromised in women with dense breast tissue-a factor that not only increases cancer risk but also obscures malignancies on imaging. Digital breast tomosynthesis has enhanced screening capabilities over traditional 2D mammography, yet limitations persist for dense breasts. In response, recent US federal legislation mandates that mammography lay summaries inform patients about the implications of breast density, including reduced detection rates and elevated risk. Additionally, insurance coverage for supplemental imaging is expanding across the United States. Supplemental screening modalities such as magnetic resonance imaging, whole-breast ultrasound, contrast-enhanced mammography, and molecular breast imaging offer improved detection in dense tissue, but guidance for average-risk women remains unclear. This lack of consensus can lead to confusion among patients and providers. This article aims to equip clinicians with a comprehensive understanding of breast density's impact on screening efficacy, the available supplemental imaging options, and current societal recommendations. By clarifying these considerations, clinicians can better navigate shared decision-making with average-risk patients regarding breast cancer screening.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты